Probiodrug

Prosidion Limited

Robert P Pauly

Hans-Ulrich Demuth

Fred Rosche

Joem Schmidt

Christopher H S McIntosh

Ray A Pederson

Jom Schmidt

Christopher Hs Mcintosh

Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.

Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals

Growing community of inventors

Vancouver, Canada

Robert P Pauly